The first designs have been released of the housing-led redevelopment of GlaxoSmithKline’s former west London HQ, drawn up by ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

In January, Johnson & Johnson (J&J), Eli Lilly, and Glaxosmithkline (GSK ... and Cynata Therapeutics (ASX:CYP). In London Bus terms, the deals run on early Sunday morning timetable and many ...

With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next. ... Read More The post Biocurious: With Mayne Pharmaceuticals under takeover offer, ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...